# AstraZeneca’s Lokelma approved in China

- Link: https://www.directorstalkinterviews.com/astrazenecas-lokelma-approved-in-china/412801878
- Published: 2020-01-06T07:28:07+00:00
- Author: Amilia Stone

**AstraZeneca **([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has announced today that _Lokelma_ has been approved in China for the treatment 
of adult patients with hyperkalaemia.

The approval by the National Medical Products Administration (NMPA) was based on
positive results from the extensive _Lokelma_ clinical trial programme and a pharmacodynamic
study in China which showed that patients receiving Lokelma experienced a significant,
rapid and sustained reduction of potassium in the blood.

In 2019, the NMPA included _Lokelma_ on the Accelerated Approval list of “Overseas
New Drugs in Clinical Urgent Needs for China”, recognising the significant unmet
need for effective medicines treating hyperkalaemia.

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said**: “This
> approval marks an important milestone for more than two million patients in China
> who suffer from hyperkalaemia. _Lokelma_ will offer the opportunity for patients
> and physicians to achieve long-term disease control and potentially reduce the
> risk of acute episodes, which can have serious, even life-threatening consequences.”

The _Lokelma_ clinical trials programme includes three double-blinded, placebo-controlled
trials and one open-label trial, where patients with hyperkalaemia were treated 
for up to 12 months. These trials showed that for patients receiving _Lokelma,_ 
the median time to achieving normal potassium levels in the blood was 2.2 hours,
with 98% achieving normal levels within 48 hours from baseline.^(1-3) _Lokelma_ 
also demonstrated a rapid reduction of potassium in the blood as early as one hour
with one dose and a sustained treatment effect for up to one year.^(1,2,4) _Lokelma_
was well tolerated, with few serious adverse events.^(2)

_Lokelma_ is approved in the US, the EU and Canada for the treatment of hyperkalaemia.
It is undergoing separate regulatory review in Japan, with a decision expected in
the first half of 2020.

**Hyperkalaemia**

Hyperkalaemia is characterised by high levels of potassium in the blood (generally
classified as >5mmol/l).^(1) The risk of hyperkalaemia increases significantly for
patients with chronic kidney disease (CKD) and for those who take common medications
for heart failure (HF), such as RAAS inhibitors, which can increase potassium in
the blood. Hyperkalaemia occurs in 23% to 47% of patients with CKD and/or HF, with
an estimated 200 million and 64 million people, respectively, living with each condition
worldwide.^(5-7) Hyperkalaemia may lead to cardiac arrest and death, with mortality
being up to 30% in patients with severe hyperkalaemia, if not treated rapidly.^(
8)

**Lokelma**

_Lokelma_ is an insoluble, non-absorbed sodium zirconium silicate, formulated as
a powder for oral suspension, that acts as a highly selective potassium-removing
medicine. It is administered orally, is odourless, tasteless and stable at room 
temperature. It has been evaluated in three double-blinded, placebo-controlled trials
and in one 12-month open-label trial in patients with hyperkalaemia.

**AstraZeneca in CVRM**

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s 
three therapy areas and is a key growth driver for the Company. By following the
science to understand more clearly the underlying links between the heart, kidneys
and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs
and improve outcomes by slowing disease progression, reducing risks and tackling
co-morbidities. The Company’s ambition is to modify or halt the natural course of
CVRM diseases and potentially regenerate organs and restore function, by continuing
to deliver transformative science that improves treatment practices and cardiovascular
health for millions of patients worldwide.

Share on:
